SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03911440

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development

A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.

NCT03911440 Atypical Pneumonia
MeSH: Pneumonia Pleuropneumonia Mycoplasma Infections Pneumonia, Mycoplasma
HPO: Pneumonia

2 Interventions

Name: Doxycycline

Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.

Type: Drug

Doxycycline

Name: Azithromycin

Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.

Type: Drug

Azithromycin


Primary Outcomes

Description: The timing (days) when fever subsides after treatment

Measure: Defervescence

Time: Up to 10 days

Secondary Outcomes

Description: The length of hospitalization

Measure: Hospital stay

Time: Up to 2 weeks

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 A2063G

In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---



HPO Nodes


HPO:
Pneumonia
Genes 117
CYBB NHLRC1 PIGN SLC25A24 CACNA1C RAG1 RAG2 EPM2A COL11A2 FMO3 SAMD9 RNF168 WAS OFD1 USB1 TNFSF12 SFTPC DOCK8 ORC6 SGCG POLA1 SLC35C1 CCDC114 NADK2 ACP5 GNPTAB CFTR NCF1 DDR2 ACTA1 KIAA0586 GAS8 SLC35A1 PEPD BLNK IRF8 CD55 GBA TCIRG1 CASP8 SRP54 NBN NCF2 CHD7 TNFRSF11A NSMCE3 ADA CR2 SELENON SP110 TERT ZAP70 GFI1 LEP ZBTB24 CFB RYR1 STAT3 TBC1D24 RNU4ATAC WDR19 IFNGR1 UNC119 JAK3 RMRP DNAI1 LIG4 TIMM8A KMT2D PANK2 ICOS SFTPA2 RNF125 ALMS1 CD19 MS4A1 EGFR DCLRE1C MTHFD1 TK2 CXCR4 NFIX IGHM KCNJ6 NFKB1 BTK IL21R NFKB2 SETBP1 TNFRSF13C ELANE TNFRSF13B SMARCD2 PRKCD CD79B CD81 CARD11 LTBP3 IGLL1 TAF1 LRBA PLG PLOD1 IL2RG CSPP1 KDM6A NIPBL CFAP410 AFF4 NOTCH3 IL7R MASP2 PNP DNMT3B PMM2 CYBA FOXP3